Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

UK’s Daily Mail Profiles One of the First Patients in Britain to Have Novilase Procedure (30 September 2019)

September 30, 2019 by Novian Health

LASER THAT REMOVES BREAST TUMOURS – WITHOUT A SCAR!

MOTHER, 69, WHO WAS ONE OF THE FIRST IN BRITAIN TO HAVE THE SURGERY REVEALS PROCEDURE TOOK LESS THAN AN HOUR AND LEFT HER WITH JUST A TINY PUNCTURE MARK

  • Frances Barr, 69, from Bristol, discovered suspicious growth in breast in 2013
  • Mother-of-two was told about trial surgery which would replace lumpectomy
  • New £300 Novilase procedure used local anaesthetic and a fine, hollow needle
  • Probe was fed through the needle and a hot laser beam destroyed the tumour
  • Procedure took less than an hour and left with a tiny puncture mark on the skin
  • Frances also had lumpectomy and lymph nodes removed two months later
  • Was more invasive, was off work for several weeks and had 1.5 inch long scar

By PAT HAGAN FOR THE DAILY MAIL

PUBLISHED: 17:10 EDT, 30 September 2019 | UPDATED: 03:17 EDT, 1 October 2019

A new laser surgery for breast cancer has just been approved for use in the UK. It leaves virtually no scars and needs only local anaesthetic.

Frances Barr, 69, a mother of two and a retired PA from Bristol, was one of the first women in Britain to have it as part of a trial, as she tells Pat Hagan.

THE PATIENT

Like all women aged over 50 in the UK, I am invited for breast cancer screening every three years. It was during one of these mammograms in 2013 that a suspicious growth was found in my right breast. It wasn’t clear whether it was cancer, and I wasn’t unduly alarmed.

But I was referred to the Bristol Breast Care Centre and, a few weeks later, underwent a second mammogram, followed by a biopsy. When I was given the results just days later, I got a terrible shock. The pea-sized growth was cancerous and I needed urgent treatment. It was devastating news. Luckily, my husband, Geoff, 79, was with me and was a tremendous comfort.

My consultant said I needed a lumpectomy to remove the tumour. This would involve an incision a couple of inches long and the removal of a small amount of surrounding ‘healthy’ tissue, too, in case any cancer cells had started to spread. This would be followed by radiotherapy to destroy lingering cells. My lymph nodes (glands in the armpits where cancer cells often migrate) would be removed just in case.

However, as I was leaving my appointment, one of the nurses mentioned that the centre was about to start a trial for a treatment that could replace a lumpectomy in women who had relatively small tumours, of less than 20mm in diameter. She arranged for me to meet cancer specialist Dr Mike Shere, who was overseeing the trial.

He explained that, instead of surgery with general anaesthetic, the new procedure used local anaesthetic. It involved inserting a fine, hollow needle through the breast tissue into the tumour. A probe would be fed through the needle and a hot laser beam would destroy the tumour. The entire thing would take less than an hour and, afterwards, I’d be left with a tiny, barely visible puncture mark.

As I was one of the first people in the world to get the treatment, and doctors were still not sure if it would work, it would have been unethical for me to have it instead of a lumpectomy — as there was a danger it wouldn’t kill off all the cancer. I was told that I would have the laser treatment followed several weeks later by a lumpectomy, so doctors could see if the treatment had worked, as well as lymph node removal.

WHAT ARE THE RISKS?

  • There are no major risks compared to a lumpectomy, but the Novilase laser treatment is currently not suitable for breast tumours bigger than 20mm in diameter.
  • Professor Philip Drew, a consultant breast surgeon at the Duchy Hospital in Truro, Cornwall, says the procedure could be particularly helpful for older women with small breast tumours who may be less able to withstand the current surgery.
  • But, he adds, ‘we need to be certain that the treatment gets rid of all the cancer: that’s the first question patients ask when they come round’.

In November 2013, I had the Novilase procedure. Dr Shere first injected local anaesthetic into the front of my right breast, then used a handheld ultrasound monitor to navigate a long needle towards the tumour.

Once the tip reached it, he fed in the laser probe to destroy the cancerous tissue. I was awake and chatted to one of the nurses throughout — I felt quite calm. The needle forcing its way in was uncomfortable, but not painful, and, afterwards, I had a cup of tea before going home.

There was some pain over the next day or so, but paracetamol took care of that. For a day, I wore a tight bandage around my chest to reduce any swelling and my breast was back to normal within a day or two.

Two months later, I had the lumpectomy and my lymph nodes removed. This was much more invasive and kept me off work for several weeks. I was left with a scar 1.5 in long and an unsightly dent in my breast from the tissue removal.

Surgeons also removed the dead tissue that had been lasered and found no trace of the cancer: the laser treatment had worked. Now, I enjoy life as much as I can, exercising and walking my dogs.

THE SPECIALIST

Dr Mike Shere is a cancer specialist at the Bristol Breast Care Centre.

Around 25,000 women a year in the UK undergo a lumpectomy for breast cancer, usually when the tumour has not spread. These are very effective at eradicating small tumours, but leave a scar. Between 1.5 and 10 per cent of lumpectomy wounds also become infected.

The new laser treatment could achieve the same results, but without the collateral damage, as the entry point where bacteria might get in is much smaller.

Our centre was one of the first in Europe to trial Novilase, and it has recently been approved in the UK, so many more women could soon benefit.

An MRI scan maps the location of the tumour, then local anaesthetic is injected into the breast, and a needle — around 4 in long — is slowly inserted, until the tip is in the centre of the tumour. The needle is attached to a handset controlled by the doctor and running parallel to it is another needle, just 15mm away, which is inserted into the breast at the same time. This has five tiny temperature sensors.

When both the needles are in position, a fibre-optic cable is fed through the needle. At the press of a button on the console, a laser beam from the fibre-optic cable penetrates the cancerous tissue. The laser takes about ten minutes to reach the desired temperature of 60c to 100c. The needle’s heat sensors reveal if it’s hot enough to be effective, or so hot that there’s a risk of damage to healthy tissue. All that’s left behind are two tiny puncture wounds, and the patient can go home straight away.

The beauty of laser therapy is that it can be safely repeated if scans reveal it didn’t destroy all of the tumour the first time around. While it’s currently only being tested on small tumours, in theory we could use several needles to treat bigger tumours.

The results of the trial, which involved 61 patients at centres around the world, were published in 2018 in Annals Of Surgical Oncology. These showed 84 per cent of patients with tumours of up to 20mm saw them completely destroyed with one treatment. Among women whose tumours measured 15mm or less, the success rate was 98 per cent — similar to lumpectomy.

Laser treatment could eventually mean an end to lumpectomies. At the moment, patients still need lymph node removal surgery, as this is standard practice, but trials are beginning to show there’s no advantage to this unless you know the cancer has spread to them. I predict routine lymph node removal could become a thing of the past within the next five years or so, by which time Novilase could be in widespread use in the NHS.

Related Posts

  • Novian Health Obtains CE Mark for Novilase Breast Therapy (16 July 2019)
  • Novian Health Chosen as Red Herring Top 100 North America Winner (05 June 2019)
  • Walter Reed Bethesda Joins Novilase Clinical Trial (9 Sept 2014)
  • Novilase Treatment for Benign Breast Tumors Featured at Breast Surgeons Meeting (04 May 2009)
  • Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors (2 Sept 2014)

Filed Under: Press Release 2019

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by